Related Experiment Video

Updated: May 25, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

[Five year-results of chemoresistance testing in cancer patients]

J Hatok1, T Matáková, J Jureceková

  • 1Ustav lekárskej biochémie, JLF UK Martin, Slovenská republika. hatok@jfmed.uniba.sk

Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|January 20, 2012
PubMed
Abstract

Insights

Chemoresistance testing in cancer patients using the MTT assay revealed significant drug resistance in acute myeloblastic leukemia and solid tumors. This in vitro method effectively identified varying patient responses to chemotherapy agents.

Area of Science:

  • Oncology
  • Translational Medicine
  • Pharmacology

Context:

  • Translational medicine bridges basic research and clinical practice for novel diagnostics and therapeutics.
  • Chemoresistance testing is crucial for optimizing cancer treatment strategies.
  • Previous experience in chemoresistance testing for oncological diseases is presented.

Purpose:

  • To evaluate in vitro chemoresistance in patients with leukemia and solid tumors.
  • To assess the efficacy of various chemotherapy agents against malignant cells.
  • To determine the utility of the MTT assay in predicting drug resistance.

Summary:

  • The study analyzed 71 leukemia patients (AML, ALL, CML) and 92 solid tumor patients (lung, gastrointestinal).
  • In vitro drug resistance was tested using the methyl-thiazol tetrazolium (MTT) assay.
  • Results indicated higher resistance in acute myeloblastic leukemia than acute lymphoblastic leukemia, and identified primary resistance rates for multiple agents in lung and gastrointestinal cancers.

Impact:

  • The MTT assay demonstrated effectiveness in identifying malignant cell resistance to cytostatics, despite limitations.
  • Findings provide insights into patient-specific chemoresistance, aiding in personalized treatment approaches.
  • Identified resistance patterns can inform the selection of chemotherapy regimens for lung and gastrointestinal cancers.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...